Goldman Sachs resumes Immunovant stock coverage with Neutral rating

Goldman Sachs initiated Immunovant (IMVT) with a Neutral rating and an $18 price target, acknowledging IMVT-1402 as a differentiated asset but citing limited near-term de-risking events and competitive concerns despite the company's strong $714 million cash position. This contrasts with H.C. Wainwright, which maintained a Buy rating while lowering its price target to $35 from $54, reflecting IMVT-1402's expanded indications and unique position in Graves' Disease, yet also factoring in emerging competitive pressures, notably from Biohaven. The divergent analyst views highlight the balance between IMVT's promising pipeline and the evolving competitive landscape in the FcRn inhibitor space.

Analysis

Immunovant (IMVT) presents a mixed investment profile characterized by divergent analyst ratings and a balance between long-term pipeline potential and near-term headwinds. Goldman Sachs initiated coverage with a 'Neutral' rating and an $18 price target, citing a lack of meaningful de-risking catalysts over the next year and concerns about advancing competitive programs. Conversely, H.C. Wainwright maintained a 'Buy' rating but significantly lowered its price target to $35 from $54, influenced by Biohaven's initiation of a rival pivotal study. The core value proposition rests on IMVT-1402, a differentiated asset viewed as a potential first-in-class treatment for indications like Graves' Disease. The company's fundamental position is strong, supported by a $714 million cash reserve sufficient to fund operations through its expected 2027 study readouts and the backing of majority holder Roivant Sciences, which mitigates intermediate-term downside risk. However, the path to commercialization, with registrational studies starting by summer 2025 and a potential launch in 2028, is long and subject to increasing competitive pressure, which tempers the outlook for near-term share outperformance.

Key Decisions for Investors

• Investors should view Immunovant as a long-term holding, as significant value inflection points tied to clinical readouts are not expected until 2027, with potential commercialization in 2028.
• Closely monitor the competitive landscape, particularly clinical trial progress from Biohaven, as this is a primary factor influencing analyst valuations and represents a key risk to IMVT's market position for its FcRn inhibitor.
• Given the lack of near-term catalysts highlighted by Goldman Sachs, consider that significant share price appreciation may be limited until the planned initiation of registrational studies in mid-2025, which could present a more strategic entry or accumulation point.